Risk Factors and Outcome of Polymicrobial Bacteremia: A Retrospective Cohort Study.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
May 2020
Historique:
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 22 5 2020
Statut: ppublish

Résumé

Recent data regarding polymicrobial bacteremia (PMB) are lacking. To characterize risk factors as well as clinical, microbiological, and prognostic patterns of patients with PMB in a modern hospital setting. A single center retrospective study including all patients diagnosed with PMB during 2013 was conducted. PMB was defined as two or more organisms cultured from the blood of the same patient within 72 hours. Patients with monomicrobial infections served as controls. There were 135 episodes (2% of all bacteremia episodes) of true PMB among 123 patients during the study period. Recent invasive procedures (odds ratio [OR] 3.59, 95% confidence interval [95%CI] 1.41-9.12, P = 0.006) and foreign bodies (OR 1.88, 95%CI 1.06-3.33, P = 0.04) were risk factors for PMB when compared with 79 patients with monomicrobial bacteremia. Central-line-associated infections were the most common infection source among patients with PMB (n=34, 28%). Enterobacteriaceae were the most commonly implicated pathogen (n=95, 77%). Non-fermenting Gram-negative bacilli were significantly more common than previously reported (n=55, 45%). Although crude 30-day mortality was higher (48% vs. 33%) in PMB patients, adjusted mortality was comparable in the two groups. PMB rate in our cohort was considerably lower than in previous reports. Central-line-associated infections were more common than classic PMB sources. Mortality remained high. Strategies for early identification and better care for these patients should be pursued.

Sections du résumé

BACKGROUND BACKGROUND
Recent data regarding polymicrobial bacteremia (PMB) are lacking.
OBJECTIVES OBJECTIVE
To characterize risk factors as well as clinical, microbiological, and prognostic patterns of patients with PMB in a modern hospital setting.
METHODS METHODS
A single center retrospective study including all patients diagnosed with PMB during 2013 was conducted. PMB was defined as two or more organisms cultured from the blood of the same patient within 72 hours. Patients with monomicrobial infections served as controls.
RESULTS RESULTS
There were 135 episodes (2% of all bacteremia episodes) of true PMB among 123 patients during the study period. Recent invasive procedures (odds ratio [OR] 3.59, 95% confidence interval [95%CI] 1.41-9.12, P = 0.006) and foreign bodies (OR 1.88, 95%CI 1.06-3.33, P = 0.04) were risk factors for PMB when compared with 79 patients with monomicrobial bacteremia. Central-line-associated infections were the most common infection source among patients with PMB (n=34, 28%). Enterobacteriaceae were the most commonly implicated pathogen (n=95, 77%). Non-fermenting Gram-negative bacilli were significantly more common than previously reported (n=55, 45%). Although crude 30-day mortality was higher (48% vs. 33%) in PMB patients, adjusted mortality was comparable in the two groups.
CONCLUSIONS CONCLUSIONS
PMB rate in our cohort was considerably lower than in previous reports. Central-line-associated infections were more common than classic PMB sources. Mortality remained high. Strategies for early identification and better care for these patients should be pursued.

Identifiants

pubmed: 32378818

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

279-284

Auteurs

Shira Goldman (S)

Department of Nephrology and Hypertension, Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Oranit Itshaki (O)

Department of Medicine A, Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Tzippy Shochat (T)

Department of Statistical Consulting Unit, Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Anat Gafter-Gvili (A)

Department of Medicine A, Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dafna Yahav (D)

Department of Infectious Diseases Unit, Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Bina Rubinovitch (B)

Department of Infection Control Unit, Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Daniel Shepshelovich (D)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Medicine I, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH